600079 人福医药
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入19,143,3755.70%24,524,74122,337,71920,548,93020,680,111
减:营业总成本16,644,2235.90%21,417,05919,851,77518,750,61318,910,754
    其中:营业成本10,192,3063.94%13,290,99212,615,13811,764,84511,999,654
               财务费用327,27254.61%304,519236,944623,308916,149
               资产减值损失(4,249)-85.22%(61,407)(88,312)(55,124)(59,357)
公允价值变动收益(7,259)-106.98%136,85543,4177,88516,403
投资收益80,482-58.97%206,785835,557306,009324,105
    其中:对联营企业和合营企业的投资收益48,9367.06%59,99222,514132,33673,166
营业利润2,655,713-3.19%3,447,1743,516,0282,249,0402,091,872
利润总额2,588,983-4.37%3,383,8293,426,0532,172,9742,027,331
减:所得税费用481,60213.55%568,563354,751354,782385,142
净利润2,107,381-7.70%2,815,2663,071,3021,818,1931,642,189
减:非控股权益517,6860.63%680,781587,194501,047636,455
股东净利润1,589,694-10.12%2,134,4852,484,1091,317,1461,005,733

市场价值指针
每股收益 (元) *0.980-10.09%1.3201.5400.8300.730
每股派息 (元) *0.150--0.4600.1600.1500.100
每股净资产 (元) *10.9476.77%10.4419.2107.9296.891
审计意见 #--标准无保留意见标准无保留意见带有强调事项段、持续经营重大不确定性段落、其他信息段落中包含其他信息未更正重大错报说明的无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容